Browse by Author

Browse by Year

Browsing publications by Huw Thomas

Newcastle AuthorsTitleYearFull text
Dr Aiste McCormick
Gavin Cuthbert
Dr Rachel O'Donnell
Dr Brian Wilson
Huw Thomas
et al.
Functional characterisation of a novel ovarian cancer cell line, NUOC-12017
Richard Noble
Dr Natalie Bell
Dr Helen Blair
Huw Thomas
Nicole Phillips
et al.
Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma2017
Carlo Bawn
Martin Galler
Huw Thomas
Suzanne Kyle
Professor Nicola Curtin
et al.
PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS2017
Dr Gary Beale
Emma Haagensen
Huw Thomas
Lan Wang
Charlotte Revill
et al.
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer2016
Emma Haagensen
Huw Thomas
Dr Ross Maxwell
Professor Herbie Newell
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-0372016
Emma Haagensen
Huw Thomas
Dr Ross Maxwell
Professor Herbie Newell
Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent2016
Dr Christopher Wong
Dr Ian Hardcastle
Christopher Matheson
Professor Herbie Newell
Dr Mangaleswaran Sivaprakasam
et al.
Structure-guided design of purine-based probes for selective Nek2 inhibition2016
Liam Cornell
Dr Joanne Munck
Laura Ogle
Catherine Willoughby
Dr Despina Televantou
et al.
DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival2015
Dr Jill Hunter
Dr Jacqueline Butterworth
Helene Sellier
Huw Thomas
Dr Christopher Bacon
et al.
The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma2015
Huw Thomas
Professor Nicola Curtin
Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself2015
1234567